Patents by Inventor Krystle LANG

Krystle LANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HCV vaccines and methods for using the same
    Patent number: 9156890
    Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a/1b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: October 13, 2015
    Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
    Inventors: David B. Weiner, Krystle A. Lang, Jian Yan, Ruxandra Draghia-Akli, Amir Khan
  • Vaccines and methods for using the same
    Patent number: 9156891
    Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: October 13, 2015
    Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
    Inventors: David B. Weiner, Krystle A. Lang-Kuhs, Jian Yan, Ruxandra Draghia-Akli, Amir S. Khan
  • Vaccines And Methods For Using The Same
    Publication number: 20150166612
    Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
    Type: Application
    Filed: November 24, 2014
    Publication date: June 18, 2015
    Inventors: David B. Weiner, Krystle A. Lang-Kuhs, Jian Yan, Ruxandra Draghia-Akli, Amir S. Khan
  • HCV VACCINES AND METHODS FOR USING THE SAME
    Publication number: 20150017197
    Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a/1b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
    Type: Application
    Filed: September 8, 2014
    Publication date: January 15, 2015
    Inventors: David B. Weiner, Krystle A. Lang, Jian Yan, Ruxandra Draghia-Akli, Amir Khan
  • HCV vaccines and methods for using the same
    Patent number: 8921536
    Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: December 30, 2014
    Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
    Inventors: David B Weiner, Krystle Lang, Jian Yan, Ruxandra Draghia-Akli, Amir S Khan
  • HCV vaccines and methods for using the same
    Patent number: 8829174
    Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1 a/1 b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: September 9, 2014
    Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
    Inventors: David B Weiner, Krystle A. Lang Kuhs, Jian Yan, Ruxandra Draghia-Akli, Amir Khan
  • HCV VACCINES AND METHODS FOR USING THE SAME
    Publication number: 20120093863
    Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
    Type: Application
    Filed: October 20, 2011
    Publication date: April 19, 2012
    Inventors: David B. WEINER, Krystle LANG, Jian YAN, Ruxandra DRAGHIA-AKLI, Amir S. KHAN
  • HCV VACCINES AND METHODS FOR USING THE SAME
    Publication number: 20120034256
    Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1 a/1 b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
    Type: Application
    Filed: October 29, 2008
    Publication date: February 9, 2012
    Inventors: David B. Weiner, Krystle A. Lang, Jian Yan, Ruxandra Draghia-Akli, Amir Khan